文献速递心律失常

脉冲场消融用于心房颤动肺静脉隔离的首次人体试验

Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation.
PubMed 文献 · J Am Coll Cardiol · 2019-05-11

两项首次人体试验评估脉冲场消融(PFA)在阵发性心房颤动中行肺静脉隔离的安全性与有效性,81例患者分别接受单相或双相PFA波形消融,随波形优化3个月隔离持久性由18%提升至100%,12个月无心律失常生存估计为87.4±5.6%。

要点

  • 波形优化后3个月全部肺静脉隔离的持久性由18%提升至100%。
  • 12个月无心律失常的Kaplan-Meier估计为87.4±5.6%。

核心结论

  • 在首次人体试验中,PFA优先作用于心肌组织,实现便捷的超快速肺静脉隔离,并具有良好持久性与长期安全性。

研究设计与样本

  • 两项首次人体试验(IMPULSE,NCT03700385;PEFCAT,NCT03714178)评估导管PFA治疗阵发性心房颤动的安全性与有效性,共81例患者,使用专有双相或单相PFA波形,未采用食管保护策略,3个月后重复有创电生理标测评估肺静脉隔离持久性。

主要发现

  • 81例患者全部肺静脉经单相(n=15)或双相(n=66)PFA急性隔离,每例递送时间≤3分钟,皮肤至皮肤手术时间92.2±27.4分钟,透视时间13.1±7.6分钟。
  • 随波形逐步优化,3个月时全部肺静脉隔离的患者比例由18%提升至100%。
  • 除1例操作相关心包填塞外,120天中位随访内无卒中、膈神经损伤、肺静脉狭窄和食管损伤等额外主要不良事件。
  • 12个月无心律失常的Kaplan-Meier估计为87.4±5.6%。

临床怎么用

  • 结果提示PFA可作为阵发性心房颤动肺静脉隔离的消融能量选择,具有超快速隔离、良好持久性和短期安全性,但需注意操作相关心包填塞风险。

局限性

  • 为首次人体试验,样本量81例,随访以120天中位随访和12个月Kaplan-Meier估计为主,缺乏与射频或冷冻消融的随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Catheter ablation of atrial fibrillation using thermal energies such as radiofrequency or cryothermy is associated with indiscriminate tissue destruction. During pulsed field ablation (PFA), subsecond electric fields create microscopic pores in cell membranes-a process called electroporation. Among cell types, cardiomyocytes have among the lowest thresholds to these fields, potentially permitting preferential myocardial ablation. OBJECTIVES: The purpose of these 2 trials was to determine whether PFA allows durable pulmonary vein (PV) isolation without damage to collateral structures. METHODS: Two trials were conducted to assess the safety and effectiveness of catheter-based PFA in paroxysmal atrial fibrillation. Ablation was performed using proprietary bipolar PFA waveforms: either monophasic with general anesthesia and paralytics to minimize muscle contraction, or biphasic with sedation because there was minimal muscular stimulation. No esophageal protection strategy was used. Invasive electrophysiological mapping was repeated after 3 months to assess the durability of PV isolation. RESULTS: In 81 patients, all PVs were acutely isolated by monophasic (n = 15) or biphasic (n = 66) PFA with ≤3 min elapsed delivery/patient, skin-to-skin procedure time of 92.2 ± 27.4 min, and fluoroscopy time of 13.1 ± 7.6 min. With successive waveform refinement, durability at 3 months improved from 18% to 100% of patients with all PVs isolated. Beyond 1 procedure-related pericardial tamponade, there were no additional primary adverse events over the 120-day median follow-up, including: stroke, phrenic nerve injury, PV stenosis, and esophageal injury. The 12-month Kaplan-Meier estimate of freedom from arrhythmia was 87.4 ± 5.6%. CONCLUSIONS: In first-in-human trials, PFA preferentially affected myocardial tissue, allowing facile ultra-rapid PV isolation with excellent durability and chronic safety. (IMPULSE: A Safety and Feasibility Study of the IOWA Approach Endocardial Ablation System to Treat Atrial Fibrillation; NCT03700385; and PEFCAT: A Safety and Feasibility Study of the FARAPULSE Endocardial Ablation System to Treat Paroxysmal Atrial Fibrillation; NCT03714178).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Reddy VY, Neuzil P, Koruth JS, et al. Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation. J Am Coll Cardiol. 2019. PMID: 31085321. doi:10.1016/j.jacc.2019.04.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。